123 related articles for article (PubMed ID: 20664968)
21. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.
Yanagisawa K; Tomida S; Shimada Y; Yatabe Y; Mitsudomi T; Takahashi T
J Natl Cancer Inst; 2007 Jun; 99(11):858-67. PubMed ID: 17551146
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancer.
Kim NY; Pyo JS
Pathol Res Pract; 2017 Jul; 213(7):778-782. PubMed ID: 28554757
[TBL] [Abstract][Full Text] [Related]
23. Demonstration of persistent tumor cells 4 weeks after radiofrequency ablation of a pulmonary adenocarcinoma.
Renaud S; Schiavon M; Santelmo N; Massard G
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):e111-3. PubMed ID: 22959321
[No Abstract] [Full Text] [Related]
24. Orai3 is a predictive marker of metastasis and survival in resectable lung adenocarcinoma.
Benzerdjeb N; Sevestre H; Ahidouch A; Ouadid-Ahidouch H
Oncotarget; 2016 Dec; 7(49):81588-81597. PubMed ID: 27835593
[TBL] [Abstract][Full Text] [Related]
25. Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.
Yang L; Tang C; Xu B; Wang W; Li J; Li X; Qin H; Gao H; He K; Song S; Liu X
PLoS One; 2015; 10(6):e0128970. PubMed ID: 26047516
[TBL] [Abstract][Full Text] [Related]
26. Wedge resection verses lobectomy for stage 1 non-small-cell lung cancer.
Warwick R; Mediratta N; Shackcloth M; Page R; McShane J; Shaw M; Poullis M
Asian Cardiovasc Thorac Ann; 2013 Oct; 21(5):566-73. PubMed ID: 24570559
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
Rades D; Setter C; Dahl O; Schild SE; Noack F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
[TBL] [Abstract][Full Text] [Related]
28. [Differential proteomic analysis of human lung adenocarcinoma cell line A-549 and of normal cell line HBE].
Zhan XQ; Guan YJ; Li C; Chen ZC; Xie JY; Chen P; Liang SP
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2002 Jan; 34(1):50-6. PubMed ID: 11958134
[TBL] [Abstract][Full Text] [Related]
29. Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system.
Carr SR; Schuchert MJ; Pennathur A; Wilson DO; Siegfried JM; Luketich JD; Landreneau RJ
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):390-7. PubMed ID: 22169444
[TBL] [Abstract][Full Text] [Related]
30. Metastatic index of non-small-cell lung cancer and long-term survival.
Poullis M; Shackcloth M; Page R; Asanti-Siaw J; Woolley S; Mediratta N
Asian Cardiovasc Thorac Ann; 2015 Feb; 23(2):185-90. PubMed ID: 25107893
[TBL] [Abstract][Full Text] [Related]
31. Discovery of new membrane-associated proteins overexpressed in small-cell lung cancer.
Ocak S; Friedman DB; Chen H; Ausborn JA; Hassanein M; Detry B; Weynand B; Aboubakar F; Pilette C; Sibille Y; Massion PP
J Thorac Oncol; 2014 Mar; 9(3):324-36. PubMed ID: 24518087
[TBL] [Abstract][Full Text] [Related]
32. Proteomics out of the archive: Two-dimensional electrophoresis and mass spectrometry using HOPE-fixed, paraffin-embedded tissues.
Kähler D; Alexander C; Schultz H; Abdullah M; Branscheid D; Lindner B; Zabel P; Vollmer E; Goldmann T
J Histochem Cytochem; 2010 Mar; 58(3):221-8. PubMed ID: 19995946
[TBL] [Abstract][Full Text] [Related]
33. Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma.
Peng XC; Gong FM; Zhao YW; Zhou LX; Xie YW; Liao HL; Lin HJ; Li ZY; Tang MH; Tong AP
PLoS One; 2011; 6(11):e27309. PubMed ID: 22087286
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow micrometastasis is associated with both disease recurrence and poor survival in surgical patients with node-negative non-small-cell lung cancer: a meta-analysis.
Deng XF; Liu QX; Zhou D; Min JX; Dai JG
Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):21-7. PubMed ID: 25883247
[TBL] [Abstract][Full Text] [Related]
35. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
36. High expression of CHRNA1 is associated with reduced survival in early stage lung adenocarcinoma after complete resection.
Chang PM; Yeh YC; Chen TC; Wu YC; Lu PJ; Cheng HC; Lu HJ; Chen MH; Chou TY; Huang CY
Ann Surg Oncol; 2013 Oct; 20(11):3648-54. PubMed ID: 23775407
[TBL] [Abstract][Full Text] [Related]
37. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.
Koike T; Koike T; Yoshiya K; Tsuchida M; Toyabe S
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):372-8. PubMed ID: 23870323
[TBL] [Abstract][Full Text] [Related]
38. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.
Jacot W; Lhermitte L; Dossat N; Pujol JL; Molinari N; Daurès JP; Maudelonde T; Mangé A; Solassol J
J Thorac Oncol; 2008 Aug; 3(8):840-50. PubMed ID: 18670301
[TBL] [Abstract][Full Text] [Related]
39. Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.
Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):358-64. PubMed ID: 23477694
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
